Statistical analysis
A sample size of 10 participants per treatment sequence provided more than 90% power to detect a difference in the AUC of change from the start of infusion of PACAP38 in STA diameter (AUCAll randomized participants who received either placebo or Lu AG09222 were included in the safety analysis; all participants who received an infusion of PACAP38 or saline and had a valid pre-infusion STA diameter measurement and a valid AUCThe primary endpoint was analyzed using an analysis of covariance (i.e., change from start of infusion in AUC